Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 986

1.

Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.

Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.

Eur J Haematol. 2004 Apr;72(4):231-8.

PMID:
15089759
2.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11. Epub 2004 Dec 30.

3.
4.

Bcr/Abl activates transcription of the Bcl-X gene through STAT5.

Gesbert F, Griffin JD.

Blood. 2000 Sep 15;96(6):2269-76.

5.

BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.

Gonzalez MS, De Brasi CD, Bianchini M, Gargallo P, Moiraghi B, Bengió R, Larripa IB.

Blood Cells Mol Dis. 2010 Oct 15;45(3):192-6. doi: 10.1016/j.bcmd.2010.07.011. Epub 2010 Aug 21.

PMID:
20728382
6.

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.

Oncogene. 2002 Dec 12;21(57):8804-16.

7.

Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.

Gaiger A, Henn T, Hörth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner K, Lion T.

Blood. 1995 Sep 15;86(6):2371-8.

8.

Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J.

Blood. 1996 Aug 1;88(3):809-16.

9.

Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.

Coppo P, Dusanter-Fourt I, Millot G, Nogueira MM, Dugray A, Bonnet ML, Mitjavila-Garcia MT, Le Pesteur D, Guilhot F, Vainchenker W, Sainteny F, Turhan AG.

Oncogene. 2003 Jun 26;22(26):4102-10.

PMID:
12821944
10.

Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells.

Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J, Djeu J, Bhalla K.

Blood. 2005 Feb 1;105(3):1246-55. Epub 2004 Sep 23.

11.

p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.

van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC.

Blood. 1996 Jun 15;87(12):5213-7.

12.

Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.

Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, Hedley DW, Shankey TV, Smith BL, Paniagua M, Goolsby CL.

Cytometry A. 2003 Aug;54(2):75-88.

13.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

14.

STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells.

de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L.

Mol Cell Biol Res Commun. 2000 May;3(5):299-305.

PMID:
10964754
15.

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.

Oncogene. 2002 Nov 21;21(53):8075-88.

16.
17.
18.

Expression of programmed cell death proteins in patients with chronic myeloid leukemia.

Strnad M, Brajuskovic G, Strelic N, Todoric-Zivanovic B, Stamatovic D, Tatomirovic Z, Magic Z.

J BUON. 2008 Jul-Sep;13(3):403-8.

PMID:
18979557
19.

Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.

Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.

Blood. 1996 Oct 15;88(8):3091-100.

20.

Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.

Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B.

Blood. 1995 Jul 15;86(2):726-36.

Supplemental Content

Support Center